In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.11%. On the other hand, the Dow ...

Ozempic, Wegovy and Mounjaro featured prominently. Known for their use in managing type 2 diabetes and aiding weight loss for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

Auvinen et al. examine genome-wide DNA methylation, imprinting, and gene expression in human placentas. Placentas from assisted reproductive technologies experience a variety of altered signaling ...

By itself, it’s not enough, but body mass index has years of evidence behind it and still has a place in clinical assessments ...

Eli Lilly (LLY) closed at $773.84 in the latest trading session, marking a -1.19% move from the prior day. The stock's change was less than the S&P 500's daily loss of 1.07%. At the same time, the Dow ...

Dr. Lilly, age 79, of Dublin, VA, passed away Christmas day in Roanoke, VA. Born April 21, 1945, in Radford, VA, he was the son of ...

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...